About Us
about Us
Master Core Technologies Achieve ABLINK
- From Drug Discovery to Drug Generation
We are a technology-driven company utilizing cutting-edge fully synthetic library technology to drive the discovery and optimization of macromolecular drugs. Using the "300-billion-level diversity" biological drug library developed by phage display and mammalian cell display technologies as a starting point, and based on the high-quality, high-quantity, validated drug development data collected and continuously generated, ABLINK is dedicated to creating a new data-driven and biology-driven AI application workflow and establishing a dry-wet combined AI-driven macromolecular drug development platform, realizing the ideal of extreme shortening of the development cycle of macromolecular drugs, and discovery and creation of limitless diversity and boundlessness in macromolecular drugs.
development history
Development History
- 2022
-
Formation of an AI-assisted macromolecular drug development team Phase I clinical trials for CAR-T drug developed in collaboration
- 2021
-
Completed Series A financing and established a "30-billion-level diversity" biological drug library
- 2019
-
Completed a "10-billion-level diversity" biological drug library Started providing commercial services
- 2016
-
Received angel financing and established the company
COMPANY HONOR
Company Honor
cooperative partner
Cooperative Partner
Many well-known brand enterprises and industry chain partners join hands to build an open and win-win industrial ecosystem
